Physiomics PLC ValiRx Agreement (0102P)
15 Febrero 2021 - 01:00AM
UK Regulatory
TIDMPYC
RNS Number : 0102P
Physiomics PLC
15 February 2021
15 February 2021
Physiomics plc
("Physiomics") or (the "Company")
ValiRx Agreement
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, is pleased to
announce that it has entered into a new agreement with ValiRx plc
(AIM:VAL), a clinical stage drug development company. The new
agreement supersedes the agreement between Physiomics and ValiRx
which was announced on 13 September 2011.
Under the terms of the new agreement, ValiRx will benefit from
Physiomics' experience in modelling the effects of prostate cancer
treatment, as well the use of the latest version of its Virtual
Tumour(TM) technology, which will be applied to derive valuable
information from the additional data generated by the completed
clinical trial of VAL201. Physiomics will also support ValiRx in
modelling the use of the VAL201 peptide in endometriosis (VAL301)
and Coronavirus (BC201).
Physiomics has developed a quantitative systems pharmacology
approach that uses pre-clinical and clinical data to model the
activity of a drug candidate. This data can be used to explore the
mechanism of action, disease impact and optimal dosing
strategies.
Physiomics will receive a fee (capped at GBP6m) of 6% of any
future net revenues that may be received by ValiRx relating to its
commercialisation of VAL201 and its derivatives in any indication,
including prostate cancer, endometriosis and treatment for
Coronavirus infection. Eligibility for part of this fee will be
conditional on completion of an agreed programme of work by
Physiomics that builds on the work already carried out under the
2011 agreement. This programme of work will start on 15 February
2021 and is required to be completed by 15 November 2021. In
recognition of the collaborative nature of this new agreement,
Physiomics will also be offered a seat on the ValiRx scientific
advisory board.
Dr Suzy Dilly, Chief Executive Officer of ValiRx, commented: "I
am pleased to be able to expand our collaboration and the scope of
work being carried out by Physiomics. Enhancing the scientific
understanding of our results using cutting edge technology ensures
we maximise the value of the data we have collected. This will help
in the design and execution of future clinical trials and support
discussions with potential new partners. We expect that outputs
from the application of Physiomics' technology will be incorporated
into scientific publications presenting the results from the VAL201
clinical trial."
Dr Jim Millen, Chief Executive Officer of Physiomics, added: "We
are delighted to be working once again with ValiRx on a programme
of work that replaces and extends that originally agreed in 2011.
Since the time of the original agreement, Physiomics has gained
significant additional experience in the modelling of prostate and
other cancers and we will be aiming to generate new insights which
can improve development outcomes."
This announcement is released by Physiomics plc and contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0) 20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary companies for further
clinical development and commercialisation.
https://www.valirx.com/
About VAL201
VAL201 is a short peptide being studied as a potential treatment
for prostate cancer. The peptide structure is inspired by the
naturally occurring androgen receptor and is designed to intercept
and prevent the binding of the androgen receptor to SRC kinase - an
enzyme implicated in cancerous cell growth pathways. By preventing
the androgen-mediated activation of SRC kinase, VAL201 can
potentially prevent cancerous cell proliferation (or growth)
without interfering with other functions of either the androgen
receptor or SRC kinase. This precision method, mimicking a natural
process, proposes a high specificity of cancer treatment with a
lower side effect profile. VAL201 was licensed from CRT (part of
CRUK) in 2010 and developed through preclinical development into
this clinical trial in patients with advanced prostate cancer. The
study was held at University College Hospital (UCLH), London.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRTTMFTMTABBAB
(END) Dow Jones Newswires
February 15, 2021 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024